Experimental drugs for bipolar psychosis

References

• Kennedy N, Everitt B, Boydell J, et al. Incidence and distribution of first-episode mania by age: results from a 35-year study. Psychol Med 2005 Jun;35(6):855–863.
   PubMed Web of Science ®Google Scholar
• Morgan VA, Mitchell PB, Jablensky AV. The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian national study of low prevalence (Psychotic) disorders. Bipolar Disord 2005 Aug;7(4):326–337.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Sachs GS. Age onset of psychotic versus non-psychotic bipolar illness in men and in women. J Affect Disord 2003 Apr;74(2):197–201.
   PubMed Web of Science ®Google Scholar
• Carvalho A, McIntyre R. Treatment-resistant mood disorders. Oxford (UK): Oxford University Press; 2015.
   Google Scholar
• Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 2005;10(10):808–819.
   PubMed Web of Science ®Google Scholar
• Fornaro M. Beyond monoamines towards the development of novel antidepressants. J Psychopathology. 2012;18:226–233.
   Google Scholar
• Fountoulakis KN, Gonda X, Vieta E, et al. Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? Ann Gen Psychiatry. 2011;10(1):8.
   PubMedGoogle Scholar
• Gould T, Quiroz J, Singh J, et al. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry. 2004;9(8):734–755.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord. 2009;11(s2):55–76.
   PubMedGoogle Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–126.
   Web of Science ®Google Scholar
• De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006;21:S11–S15.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second‐generation antipsychotics. Bipolar Disord. 2008;10(7):788–797.
   PubMed Web of Science ®Google Scholar
• Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111(1):9–16.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker J, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–424.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(5):S7–S14.
   PubMedGoogle Scholar
• Martínez-Arán A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004;161(2):262–270.
   PubMed Web of Science ®Google Scholar
• Torres I, DeFreitas C, DeFreitas V, et al. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med. 2011;41(05):971–982.
   PubMedGoogle Scholar
• Byerly MJ, Nakonezny PA, Bettcher BM, et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res. 2006;86(1):244–250.
   PubMed Web of Science ®Google Scholar
• Coffman JA, Bornstein RA, Olson SC, et al. Cognitive impairment and cerebral structure by MRI in bipolar disorder. Biol Psychiatry. 1990;27(11):1188–1196.
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Koshy AS, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat. 2016;12:1–17.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1):91–100.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262(1):1–48.
   PubMedGoogle Scholar
• Ayd F. The early history-of modern psychopharmacology. Neuropsychopharmacology. 1991;5(2):71–84.
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison K. Manic-depressive illness: bipolar disorders and recurrent depression. Oxford (UK): Oxford University Press; 2007.
   Google Scholar
• Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63–101.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel R, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–447.
   PubMed Web of Science ®Google Scholar
• Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology. 2003;166(4):315–332.
   PubMed Web of Science ®Google Scholar
• Muskin PR, Gerbarg PL, Brown RP. Complementary and Integrative therapies for psychiatric disorders, an issue of psychiatric clinics. Maryland Heights, (MO): Elsevier Health Sciences; 2013.
   Google Scholar
• Kulkarni J, Filia S, Berk L, et al. Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC Psychiatry. 2012;12:228.
   PubMed Web of Science ®Google Scholar
• Goodwin Go, Psychopharmacology CGotBAf. Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E. Psychoeducation manual for bipolar disorder. Cambridge, (UK): Cambridge University Press; 2006.
   Google Scholar
• Bauer MS, Mitchner L What is a “mood stabilizer”? An evidence-based response. Am J Psychiatry. 2014;161(1):3–18.
   Google Scholar
• Garver DL, Hutchinson LJ. Psychosis, lithium-induced antipsychotic response, and seasonality. Psychiatry Res. 1988 Dec;26(3):279–286.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xu X, Li J, et al. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res. 2011 Oct;21(10):1424–1435.
   PubMed Web of Science ®Google Scholar
• Rybakowski J, Ashcroft I, Skolasińska-Judek M, et al. The faces of manic-depressive illness. Poznan, Poland: Termedia Wydawnictwa Medyczne; 2009.
   Google Scholar
• Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2004 Feb;65(2):177–186.
   PubMed Web of Science ®Google Scholar
• Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG. Drugs under early investigation for the treatment of bipolar disorder. Expert Opin Investig Drugs. 2015;24(4):477–490.
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza A, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–817.
   PubMed Web of Science ®Google Scholar
• Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct. 2012;8(1):61.
   PubMed Web of Science ®Google Scholar
• Dodd S, Maes M, Anderson G, et al. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuro-Psychopharmacology Biol Psychiatry. 2013;42:135–145.
   PubMed Web of Science ®Google Scholar
• Manji H, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry. 2001;7:S46–S56.
   Web of Science ®Google Scholar
• Shaltiel G, Chen G, Manji HK. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol. 2007;7(1):22–26.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos S, Konstantakopoulos G. Pharmacological agents under research for the maintenance treatment in bipolar disorder. Psychiatriki. 2015 Jul-Sep;26(3):169–180.
   PubMedGoogle Scholar
• Dodd S. Novel therapeutic targets for bipolar disorder. Oxford (UK):Treatment-Resistant Mood Disorders; 2015.
   Google Scholar
• Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for bipolar disorders biomarkers task force. Aust NZ J Psychiatry. 2013 Apr;47(4):321–332.
   PubMed Web of Science ®Google Scholar
• Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006;40(4):322–335.
   PubMed Web of Science ®Google Scholar
• McNamara RK, Lotrich FE. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother. 2012;12(9):1143–1161.
   PubMed Web of Science ®Google Scholar
• Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehavioral Rev. 2012;36(2):764–785.
   PubMed Web of Science ®Google Scholar
• Martino M, Rocchi G, Escelsior A, et al. Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Current Neuropharmacology. 2012;10(2):97.
   PubMed Web of Science ®Google Scholar
• Kim Y-K, Jung H-G, Myint A-M, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1):91–95.
   PubMed Web of Science ®Google Scholar
• Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015 Mar;2(3):258–270.
   PubMed Web of Science ®Google Scholar
• Karam CS, Ballon JS, Bivens NM, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci. 2010 Aug;31(8):381–390.
   PubMed Web of Science ®Google Scholar
• Maes M, Fišar Z, Medina M, et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20(3):127–150.
   PubMedGoogle Scholar
• Olsson SK, Sellgren C, Engberg G, et al. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012 Nov;14(7):719–726.
   PubMed Web of Science ®Google Scholar
• Lavebratt C, Olsson S, Backlund L, et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry 2014;19(3):334–341.
   PubMed Web of Science ®Google Scholar
• Gould TD, Einat H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehavioral Rev. 2007;31(6):825–831.
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13(10):1161–1169.
   PubMed Web of Science ®Google Scholar
• Peedicayil J. Epigenetic approaches for bipolar disorder drug discovery. Expert Opin Drug Discov. 2014;9(8):917–930.
   PubMed Web of Science ®Google Scholar
• Sanches M, Soares JC. New drugs for bipolar disorder. Curr Psychiatry Rep. 2011 Dec;13(6):513–521.
   PubMed Web of Science ®Google Scholar
• Marneros A, Akiskal HS. The overlap of affective and schizophrenic spectra. Cambridge (UK): Cambridge university press; 2006.
   Google Scholar
• Fornaro M, Aguglia E, Dell’Osso L, et al. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? Expert Opin Pharmacother. 2011;12(18):2817–2831.
   PubMed Web of Science ®Google Scholar
• Craddock N, O’Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet. 2005;42(3):193–204.
   PubMed Web of Science ®Google Scholar
• Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nature Communications. 2013;4:1332.
   PubMed Web of Science ®Google Scholar
• Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci. 2003;1003(1):119–130.
   PubMedGoogle Scholar